Alemtuzumab versus interferon beta-1a: implications for pathology and trial design

Henry F. McFarland

doi:10.1016/S1474-4422(08)70280-1

Alemtuzumab versus interferon beta-1a: implications for pathology and trial design

Henry F. McFarland

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	26-28
Number of pages	3
Journal	The Lancet Neurology
Volume	8
Issue number	1
DOIs	https://doi.org/10.1016/S1474-4422(08)70280-1
State	Published - Jan 2009
Externally published	Yes

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1016/S1474-4422(08)70280-1

Cite this

@article{389e5bd8489e48b3bb57475b12be980f,

title = "Alemtuzumab versus interferon beta-1a: implications for pathology and trial design",

author = "McFarland, \{Henry F.\}",

year = "2009",

month = jan,

doi = "10.1016/S1474-4422(08)70280-1",

language = "English (US)",

volume = "8",

pages = "26--28",

journal = "The Lancet Neurology",

issn = "1474-4422",

publisher = "Elsevier Ltd",

number = "1",

}

TY - JOUR

T1 - Alemtuzumab versus interferon beta-1a

T2 - implications for pathology and trial design

AU - McFarland, Henry F.

PY - 2009/1

Y1 - 2009/1

UR - https://www.scopus.com/pages/publications/57249084210

UR - https://www.scopus.com/pages/publications/57249084210#tab=citedBy

U2 - 10.1016/S1474-4422(08)70280-1

DO - 10.1016/S1474-4422(08)70280-1

M3 - Article

C2 - 19081510

AN - SCOPUS:57249084210

SN - 1474-4422

VL - 8

SP - 26

EP - 28

JO - The Lancet Neurology

JF - The Lancet Neurology

IS - 1

ER -

Alemtuzumab versus interferon beta-1a: implications for pathology and trial design

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this